Live Attenuated Influenza Virus Expressing Human Interleukin-2 Reveals Increased Immunogenic Potential in Young and Aged Hosts
- 1 December 2006
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (23) , 11621-11627
- https://doi.org/10.1128/jvi.01645-06
Abstract
Despite the reported efficacy of commercially available influenza virus vaccines, a considerable proportion of the human population does not respond well to vaccination. In an attempt to improve the immunogenicity of live influenza vaccines, an attenuated, cold-adapted (ca) influenza A virus expressing human interleukin-2 (IL-2) from the NS gene was generated. Intranasal immunization of young adult and aged mice with the IL-2-expressing virus resulted in markedly enhanced mucosal and cellular immune responses compared to those of mice immunized with the nonrecombinantcaparent strain. Interestingly, the mucosal immunoglobulin A (IgA) and CD8+T-cell responses in the respiratory compartment could be restored in aged mice primed with the IL-2-expressing virus to magnitudes similar to those in young adult mice. The immunomodulating effect of locally expressed IL-2 also gave rise to a systemic CD8+T-cell and distant urogenital IgA response in young adult mice, but this effect was less distinct in aged mice. Importantly, only mice immunized with the recombinant IL-2 virus were completely protected from a pathogenic wild-type virus challenge and revealed a stronger onset of virus-specific CD8+T-cell recall response. Our findings emphasize the potential of reverse genetics to improve the efficacy of live influenza vaccines, thus rendering them more suitable for high-risk age groups.Keywords
This publication has 77 references indexed in Scilit:
- Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteinsJournal of General Virology, 2005
- Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming StrategyThe Journal of Infectious Diseases, 2005
- Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platformsVaccine, 2005
- Live cold-adapted influenza A vaccine produced in Vero cell lineVirus Research, 2004
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- Correlates of Immune Protection Induced by Live, Attenuated, Cold‐Adapted, Trivalent, Intranasal Influenza Virus VaccineThe Journal of Infectious Diseases, 2000
- The defects in effector generation associated with aging can be reversed by addition of IL-2 but not other related γc-receptor binding cytokinesVaccine, 2000
- Chimeric Influenza Virus Replicating Predominantly in the Murine Upper Respiratory Tract Induces Local Immune Responses against Human Immunodeficiency Virus Type 1 in the Genital TractThe Journal of Infectious Diseases, 1998
- Increased Anti-Influenza A Virus Cytotoxic T Cell Activity following Vaccination of the Chronically III Elderly with Live Attenuated or Inactivated Influenza Virus VaccineThe Journal of Infectious Diseases, 1995
- Cytotoxic T-Cell Immunity to InfluenzaNew England Journal of Medicine, 1983